TrialCancer communications (London, England)2025

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.

Li Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.